Boehringer Ingelheim and Enara Bio join forces to develop new Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio reported that they have entered into a strategic partnership and licensing agreement to study and
Read moreBoehringer Ingelheim and Enara Bio reported that they have entered into a strategic partnership and licensing agreement to study and
Read moreUtilising Surface Plasmon Resonance (SPR) analysis for drug development or drug discovery can make a big impact. SPR analysis can
Read morePhenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read moreViiV Healthcare’s GEMINI studies showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine, appeared to have non-inferior potency in
Read moreBristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read moreHarbour BioMed, a global clinical stage biopharmaceutical company developing novel therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19,
Read moreScientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read moreSwiss pharma giant Roche has received Emergency Use Authorisation (EUA) from the FDA for its latest COVID-19 antibody test –
Read moreNew post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read moreNubilaria is providing it’s innovative ACTide EDC system free in support of a clinical study for COVID-19 related ARDS intensive
Read more